Home » New Coronary Vaccine: Why the emergency use of Taiwan’s authorized “high-end” vaccine sparks fierce debate-BBC News

New Coronary Vaccine: Why the emergency use of Taiwan’s authorized “high-end” vaccine sparks fierce debate-BBC News

by admin

Image source,Getty Images

The Food and Drug Administration of Taiwan’s Ministry of Health and Welfare announced that an expert review meeting has been completed this week (July 17) and an application for the “Emergency Right to Use” (EUA) of high-end new coronary pneumonia vaccines has been approved, allowing project manufacturing. It is expected to be available in August this year at the earliest. Provided for Taiwanese people over the age of 20 to fight.

According to the information published by the Director of Taiwan Food and Drug Administration, Wu Xiumei, 21 experts attended the review meeting. Among them, the chairman did not participate in the voting, 18 agreed, 1 supplemented the reconsideration, and 1 disagreed. Taiwan’s Minister of Health and Welfare Chen Shizhong said that these are all scientific review results and will be sent to the vaccine team for discussion as soon as possible.

The high-end is Taiwan’s first domestically-made new crown vaccine approved and approved, and the second self-made vaccine “Lianya” is also accelerating research and development. However, because high-end vaccines were first introduced in the third phase of trials with “immune bridging”, which is different from most international mainstream vaccines, it has aroused fierce public opinion in Taiwan.

Kuomintang Chairman Jiang Qichen went to the Taipei Prefectural Prosecutor’s Office today to ring the bell to accuse Chen Shizhong and the Ministry of Health and Welfare of “crimes for profit”, saying that the purchase of high-end vaccines of up to NT$4 billion did not meet international standards. He hopes judicial investigations.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy